Big Pharma Tries Out New Class On The Diabetes Block: SGLT-2
This article was originally published in Pharmaceutical Approvals Monthly
Could controlling type 2 diabetes be as simple as dumping excess sugar out of the body via the urine? Some Big Pharmas are betting on it, and with good Phase II results rolling in, enthusiasm is growing for a new mechanism of action that targets glucose in the kidneys instead of tinkering with insulin.
You may also be interested in...
FAERS reports identify cases of diabetic ketoacidosis, ordinarily rare in type 2 diabetes, which were not associated with high blood sugar levels.
Firm now faces the commercial gauntlet of establishing an inhaled insulin in the crowded diabetes market.
AstraZeneca’s SGLT-2 inhibitor Farxiga (dapagliflozin) finally clears FDA, and without a black box warning on bladder cancer risk – allowing the drug to compete with J&J’s first-to-market Invokana.